FindTrial
Sign In

The new use of histoglob injection in people with allergic eye diseases

The naive use of Histoglob in VKC- a pilot study - Nil

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/06/069674
Enrollment
15
Registered
2024-06-28
Start date
Unknown
Completion date
Unknown
Last updated
2024-07-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: H101- Acute atopic conjunctivitis

Interventions

Intervention1: Injection Histoglob: Giving 1 ml dose of histoglob injection sub cutaneously at weekly interval for three weeks Intervention2: Histoglob injection: Histoglob injection will be given sub

Sponsors

Sankara Eye Hospital
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Subjects with newly diagnosed and recurrent allergic eye diseases

Exclusion criteria

Exclusion criteria: Symptomatic patients of less than 6 months duration

Design outcomes

Primary

MeasureTime frame
The primary outcome is to check how much reduction in the steroid dependence occurs as a result of intervention of this injection.Timepoint: The outcomes will be assessed and compared as baseline, week 1, 2 and 3 post injection.—

Secondary

MeasureTime frame
Minimising the steroid induced complications like glaucoma and cataract To bring down the cost of treatmentTimepoint: 3 months—

Countries

India

Contacts

Public ContactDr Manmeet Singh

Sankara Eye Hospital

sudhakar@sankaraeye.com

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026